Conference Call with Granules India Management and Analysts on Q4FY22 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals firm Granules India declares Q4FY22 result: Granules India reports Income from operations at INR 1,030 Cr up 29% YoY, EBITDA at INR 193 Cr, EBITDA Margin at 19%; PAT at INR 111 Cr. The Board of Directors have recommended final dividend of 75 paise per equity share of Re.1/- each in addition to interim dividend of 75 paise per equity share of Re.1/- each paid during the year. Revenue for Q4FY22 stood at INR 1,030Crs, growth of 29% YoY across all geographies and segments. Revenue share from Europe increased to 21.5% when compared to 14.5% YoY. Increase in Revenue, EBITDA and PAT in Q4FY22 compared to Q3FY22, despite adverse business condition arising out of supply constraints of Para Amino Phenol (PAP), other input price cost increase and logistic cost increase. Revenue share of non-core molecules stood at 19% on a full year basis versus 16% in the previous year, in line with our long-term strategy During the quarter we filed one ANDA, two US DMF, and received two ANDA approvals. Commenting on the results, Dr Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India Limited said, “FY 22 has been a challenging year for the industry in the face of adverse external environment with headwinds around the availability and price for Raw Materials, Solvents, Catalysts, uncertainties arising out of Ukraine-Russia conflict as well as reemergence of Covid cases in China. The global supply chain and logistics continue to remain under duress. In face of these challenges, Granules has demonstrated great resilience and I am happy with the performance of the Company. While we strive for continued improvement in our financial performance in the short term, we are working on long term strategy for making ourselves self-sustainable and overcome most of the challenges that we are facing now. We are now embarking on a new journey to reimagine our business model and transform Granules to an Innovative, science & technology driven organization, with responsible sustainable operations.” Result PDF